Rankiteo Logo
Rankiteo
Leader in Cyber Underwriting
Loading...
NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop
WindowsmacOSLinux
Download

Comparison Overview

Novartis Hong KongNovartis Hong Kong
VS
AUROBINDO PHARMA LTDAUROBINDO PHARMA LTD
Novartis Hong Kong

Novartis Hong Kong

Suite 2303-08, 23/F, 1111 King’s Road, Taikoo Shing Hong Kong, HONG KONG, undefined, undefined, HK

Last Update: 07/12/2025

View Profile
Between 750 and 799
https://www.novartis.com/hk-zh/
751/1000Fair

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million pe...

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:29
Subsidiaries:43
12-month incidents
0
Known data breaches
0
Attack type number
0
AUROBINDO PHARMA LTD

AUROBINDO PHARMA LTD

Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District,, Hyderabad, 500032, IN

Last Update: 03/04/2026

View Profile
Between 750 and 799
https://www.aurobindo.com/
778/1000Fair

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, brand...

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:14,862
Subsidiaries:0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Ranges Comparison

Based On Specific Ai Models Category
Novartis Hong Kong

Novartis Hong Kong

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA
AUROBINDO PHARMA LTD

AUROBINDO PHARMA LTD

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Hong Kong in 2026.

Incidents

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for AUROBINDO PHARMA LTD in 2026.

Incidents

Incident History - Novartis Hong Kong (X = Date, Y = Severity)

Novartis Hong Kong cyber incidents detection timeline including parent company and subsidiaries.

R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Incident History - AUROBINDO PHARMA LTD (X = Date, Y = Severity)

AUROBINDO PHARMA LTD cyber incidents detection timeline including parent company and subsidiaries.

No timeline data available
R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Notable Incidents

Last Cyber / HR Incidents / Global...
Novartis Hong Kong

Novartis Hong Kong

Incidents
No explicit notable incidents reported.
AUROBINDO PHARMA LTD

AUROBINDO PHARMA LTD

Incidents
No explicit notable incidents reported.

FAQ

Between Novartis Hong Kong company and AUROBINDO PHARMA LTD company, which one has the best AI Cybersecurity Score ?
Between Novartis Hong Kong company and AUROBINDO PHARMA LTD company, which one has experienced more cyber incidents in the past ?
Between Novartis Hong Kong company and AUROBINDO PHARMA LTD company, which one has experienced more cyber incidents this year ?
Between Novartis Hong Kong company and AUROBINDO PHARMA LTD company, which one has experienced at least one ransomware attack ?
Between Novartis Hong Kong company and AUROBINDO PHARMA LTD company, which one has experienced at least one data breach ?
Between Novartis Hong Kong company and AUROBINDO PHARMA LTD company, which one has experienced at least one targeted cyberattack ?
Between Novartis Hong Kong company and AUROBINDO PHARMA LTD company, which one has experienced at least one vulnerability ?
Between Novartis Hong Kong company and AUROBINDO PHARMA LTD company, which one holds the most compliance certifications ?
Between Novartis Hong Kong company and AUROBINDO PHARMA LTD company, which one holds the fewest compliance certifications ?
Between Novartis Hong Kong company and AUROBINDO PHARMA LTD company, which one has the most subsidiaries ?
Between Novartis Hong Kong company and AUROBINDO PHARMA LTD company, which one has the largest number of employees ?
Between Novartis Hong Kong and AUROBINDO PHARMA LTD, which company holds both SOC 2 Type 1 certifications ?
Between Novartis Hong Kong and AUROBINDO PHARMA LTD, which company holds both SOC 2 Type 2 certifications ?
Which company is ISO 27001 certified - Novartis Hong Kong or AUROBINDO PHARMA LTD ?
Which company is PCI DSS compliant - Novartis Hong Kong or AUROBINDO PHARMA LTD ?
Between Novartis Hong Kong and AUROBINDO PHARMA LTD, which company complies with HIPAA regulations for healthcare data ?
Between Novartis Hong Kong and AUROBINDO PHARMA LTD, which company complies with GDPR requirements ?

Latest Global CVEs

CVE-2026-61246
SUMMARY

Vulnerability in the Oracle Platform Security for Java product of Oracle Fusion Middleware (component: Centralized Thirdparty Jars). Supported versions that are affected are 12.2.1.4.0 and 14.1.2.0.0. Easily exploitable vulnerability allows low privileged attacker with network access via HTTP to compromise Oracle Platform Security for Java. Successful attacks of this vulnerability can result in takeover of Oracle Platform Security for Java. CVSS 3.1 Base Score 8.8 (Confidentiality, Integrity and Availability impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H).

PUBLISHED
Date2026-07-22
UPDATED
Date2026-07-22
RISK INFORMATION (Score: 8.8)
CVSS3
Base Score: 8.8
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
IMPACT SCORE
5.9
EXPLOITABILITY
2.8
REFERENCES
CVE-2026-60455
SUMMARY

Vulnerability in the Oracle Platform Security for Java product of Oracle Fusion Middleware (component: Centralized Thirdparty Jars). Supported versions that are affected are 12.2.1.4.0 and 14.1.2.0.0. Easily exploitable vulnerability allows low privileged attacker with network access via HTTP to compromise Oracle Platform Security for Java. Successful attacks of this vulnerability can result in takeover of Oracle Platform Security for Java. CVSS 3.1 Base Score 8.8 (Confidentiality, Integrity and Availability impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H).

PUBLISHED
Date2026-07-22
UPDATED
Date2026-07-22
RISK INFORMATION (Score: 8.8)
CVSS3
Base Score: 8.8
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
IMPACT SCORE
5.9
EXPLOITABILITY
2.8
REFERENCES
CVE-2026-60439
SUMMARY

Vulnerability in the Oracle Platform Security for Java product of Oracle Fusion Middleware (component: Centralized Thirdparty Jars). Supported versions that are affected are 12.2.1.4.0 and 14.1.2.0.0. Easily exploitable vulnerability allows low privileged attacker with network access via HTTP to compromise Oracle Platform Security for Java. Successful attacks of this vulnerability can result in takeover of Oracle Platform Security for Java. CVSS 3.1 Base Score 8.8 (Confidentiality, Integrity and Availability impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H).

PUBLISHED
Date2026-07-22
UPDATED
Date2026-07-22
RISK INFORMATION (Score: 8.8)
CVSS3
Base Score: 8.8
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
IMPACT SCORE
5.9
EXPLOITABILITY
2.8
REFERENCES
CVE-2026-60373
SUMMARY

Vulnerability in the Oracle Platform Security for Java product of Oracle Fusion Middleware (component: Centralized Thirdparty Jars). Supported versions that are affected are 12.2.1.4.0 and 14.1.2.0.0. Easily exploitable vulnerability allows low privileged attacker with network access via HTTP to compromise Oracle Platform Security for Java. Successful attacks of this vulnerability can result in takeover of Oracle Platform Security for Java. CVSS 3.1 Base Score 8.8 (Confidentiality, Integrity and Availability impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H).

PUBLISHED
Date2026-07-22
UPDATED
Date2026-07-22
RISK INFORMATION (Score: 8.8)
CVSS3
Base Score: 8.8
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
IMPACT SCORE
5.9
EXPLOITABILITY
2.8
REFERENCES
CVE-2026-60372
SUMMARY

Vulnerability in the Oracle Platform Security for Java product of Oracle Fusion Middleware (component: Centralized Thirdparty Jars). Supported versions that are affected are 12.2.1.4.0 and 14.1.2.0.0. Easily exploitable vulnerability allows unauthenticated attacker with network access via HTTP to compromise Oracle Platform Security for Java. Successful attacks of this vulnerability can result in takeover of Oracle Platform Security for Java. CVSS 3.1 Base Score 9.8 (Confidentiality, Integrity and Availability impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H).

PUBLISHED
Date2026-07-22
UPDATED
Date2026-07-22
RISK INFORMATION (Score: 9.8)
CVSS3
Base Score: 9.8
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
IMPACT SCORE
5.9
EXPLOITABILITY
3.9
REFERENCES